Germany's Sartorius Breaks Ground on Raw Material Production and Research Facility for Biopharmaceuticals in Songdo

Target Completion in the Second Half of 2025

[Asia Economy Reporter Park Hyesook] German multinational company Sartorius, specializing in raw materials and equipment for biopharmaceuticals, has begun construction of production and research facilities in Songdo International City, Incheon.

According to the Incheon Free Economic Zone Authority on the 14th, Sartorius Korea Operations, the Korean subsidiary of Sartorius, started construction of a biopharmaceutical core raw material production facility and related process research facilities on an industrial site of 24,000㎡ in Songdo-dong, Yeonsu-gu. The completion is scheduled for the second half of 2025.

This facility will produce single-use bags (disposable containers for culturing cells and viruses), cell culture media (liquid substances required by cultures to grow cells), and pharmaceutical filters (filters that remove impurities and harmful bacteria from medicines), and will be developed as a hub for global exports.

Additionally, research and development in biopharmaceutical process fields and educational projects will be promoted, contributing to domestic technology transfer and the co-growth of related industries.

Sartorius Songdo Production and Research Facility Site [Provided by Incheon Free Economic Zone Authority]

Founded in Germany in 1870, Sartorius is a global leading company in the bio research process field, supplying products and equipment related to life sciences research and processes, and supporting related technical services.

It operates production facilities, research centers, sales, education, logistics, and service branches in over 60 cities worldwide, with approximately 14,000 employees as of the end of 2021.

In South Korea, Sartorius Korea, Sartorius Korea Biotech, and Sartorius Korea Operations are operating, with Sartorius Korea Operations leading the Songdo project.

Kim Jin-yong, head of the Incheon Free Economic Zone Authority, stated, "With this groundbreaking, it has been confirmed that Songdo is the optimal location for Sartorius's goal of establishing a foothold for entry into the Asian market and is emerging as a global bio hub. We will provide maximum support so that Songdo can become a global hub not only for biopharmaceutical production but also for raw material supply."